Aytu Biopharma (AYTU) Corporate presentation summary

Strategic realignment and business focus

• Shifted to a profitable prescription pharmaceutical business, exiting consumer health and pipeline R&D, with $34.7M adjusted EBITDA improvement over four years.

• Key events include suspension of clinical programs, refinancing, outsourcing manufacturing, and divesting consumer health.

• Exclusive agreement to commercialize EXXUA in the US, with launch planned for late 2025/early 2026.

Product portfolio and innovation

• Focused on novel, patent-protected CNS therapeutics, especially for MDD and ADHD.

• EXXUA is the first and only selective 5-HT1A agonist approved for MDD in adults, offering a unique mechanism of action and favorable side effect profile.

• ADHD and pediatric brands include Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, and Tri-Vi-Flor.

Commercial infrastructure and patient access

• Proprietary Aytu RxConnect program ensures broad, affordable access and high patient adherence, with over 1,000 pharmacies nationwide.

• Lean, scalable commercial infrastructure with a direct sales force and analytics platform supports rapid expansion.

• Launch strategy for EXXUA includes targeted sales force, virtual promotion, and broad retail distribution.